We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

171 hedge funds and large institutions have $2.11B invested in Portola Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 69 increasing their positions, 54 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

28% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 54

7% more funds holding

Funds holding: 160171 (+11)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

4% less capital invested

Capital invested by funds: $2.2B → $2.11B (-$93.9M)

71% less call options, than puts

Call options by funds: $2.9M | Put options by funds: $10.1M

Holders
171
Holders Change
+11
Holders Change %
+6.88%
% of All Funds
4.77%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
22
Increased
69
Reduced
54
Closed
10
Calls
$2.9M
Puts
$10.1M
Net Calls
-$7.23M
Net Calls Change
-$11M
Name Holding Trade Value Shares
Change
Change in
Stake
AA
151
ALPS Advisors
Colorado
$35.1K +$1.48M +30,616 +59%
Victory Capital Management
152
Victory Capital Management
Texas
$29K +$2.46K +51 +8%
BJ
153
BlackRock Japan
Japan
$23K +$2.36K +49 +10%
Zurich Cantonal Bank
154
Zurich Cantonal Bank
Switzerland
$20K +$14.1K +293 +158%
Bank of Montreal
155
Bank of Montreal
Ontario, Canada
$20K +$23K +477 New
WA
156
WFG Advisors
Texas
$19K
OSNBOA
157
Old Second National Bank of Aurora
Illinois
$16K
KCM
158
Karp Capital Management
California
$15K +$16.9K +350 New
Walleye Trading
159
Walleye Trading
New York
$13K +$9.65K +200 +200%
CHP
160
Cable Hill Partners
Oregon
$12K
PAM
161
Panagora Asset Management
Massachusetts
$11K -$9.7K -201 -44%
ClearBridge Investments
162
ClearBridge Investments
New York
$11K
CPIG
163
Chicago Partners Investment Group
Illinois
$9K +$4.83K +100 +100%
HF
164
Hoxton Financial
West Virginia
$8K +$9.12K +189 New
EWM
165
Edge Wealth Management
New York
$6K
FNBT
166
FineMark National Bank & Trust
Florida
$6K
FWM
167
Focused Wealth Management
New York
$5K
DADC
168
D.A. Davidson & Co
Montana
$3K +$1.83K +38 +83%
Manulife (Manufacturers Life Insurance)
169
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.28K +$38.4K +795 +3%
FPFS
170
First Personal Financial Services
North Carolina
$1K
Fifth Third Bancorp
171
Fifth Third Bancorp
Ohio
$1K +$1.35K +28 New
OTPPB
172
Ontario Teachers' Pension Plan Board
Ontario, Canada
-$9.25M -203,156 Closed
PA
173
Perceptive Advisors
New York
-$5.06M -111,103 Closed
LCM
174
Laurion Capital Management
New York
-$4.92M -108,000 Closed
TI
175
Trexquant Investment
Connecticut
-$815K -17,900 Closed

PTLA Hedge Fund Activity: Q3 2015 in Review

171 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2015, worth a combined $2.11B — down 4.3% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PTLA positions and 10 closed out — a net gain of 12 holders — while 69 added to existing stakes and 54 trimmed.

The largest buyer was Millennium Management, adding an estimated $30.8M. The largest seller was Wellington Management Group, cutting an estimated $31.1M.

  • 171 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2015, up from 160 in Q2 2015.
  • Funds reported $2.11B of Portola Pharmaceuticals, Inc. stock for Q3 2015, down 4.3% quarter-over-quarter.
  • 22 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2015 and 10 closed out, a net change of +12 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q3 2015 was Millennium Management, an estimated $30.8M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q3 2015 was Wellington Management Group, an estimated $31.1M sold.

Based on aggregated 13F filings for Q3 2015.